Paid to delay: The Tipline for 10 September 2021

Bausch Health has agreed to pay $300 million to settle claims it illegally prevented the launch of a rival diabetes drug. But it appears the pharmaceutical company still may come out on top. In the second half of 2015 alone, Bausch’s profits spiked by $350 million after it raised the wholesale cost of Glumetza from just over $5 to more than $50 a pill. Meanwhile, a division of the Department of Health and Human Services has proposed banning pay-for-delay agreements entirely.

Get unlimited access to all Global Competition Review content